Rasagiline and Minocycline are Currently in Clinical Trials as Neuroprotective Agents for PD Rasagiline is a selective and potent propargylamine MAO-B inhibitor (Tatton et al., 2003), that reduces MPTP and 6-OHDA toxicity in PC12 and SH-SY5Y cells, (Maruyama et al., 2000) and is neuroprotective in vivo (Heikkila et al., 1985
Interregional variation of longitudinal relaxation rates in human brain at 3.0 T: relation to estimated iron and water contents
Staying the Course The journey to better metabolic health is a marathon, not a sprint
Conclusion In conclusion, while GLP-1 receptor agonists hold promise for those genuinely battling obesity or diabetes, their misuse in Dubai as a cosmetic weight-loss shortcut represents a troubling trend
Standard GLP-1 receptor agonists such as semaglutide work by enhancing insulin secretion, suppressing appetite, and slowing gastric emptying